OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial Board	145
Editorial Board	85
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	73
Editorial Board	69
Thiazide-induced hyponatremia	66
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	60
Surgery for prolactinoma	59
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	57
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	53
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	52
The role of androgens in transgender medicine	45
Sexual health and contraception in the menopause journey	42
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	41
Coronavirus disease 2019 and vitamin D	39
Editorial Board	35
Immune checkpoint inhibitor-related thyroid dysfunction	35
Impulse control disorders and dopamine agonists	33
Editorial Board	32
Cardiometabolic outcomes of early onset hypogonadism in males	31
Remnant lipoprotein particles and cardiovascular disease risk	31
Haematological actions of androgens	31
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	30
Editorial Board	30
Type 1 diabetes related to immune checkpoint inhibitors	29
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	27

Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	27
Radioiodine therapy in the different stages of differentiated thyroid cancer	27
Medullary thyroid cancer - An update	27
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25
Non-oestrogen-based and complementary therapies for menopause	25
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	25
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Approach to patients with elevated low-density lipoprotein cholesterol levels	24
Immune checkpoint inhibitor-related hypophysitis	23
Pathophysiology of thyroid-associated orbitopathy	23
Editorial Board	22
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	22
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Editorial Board	22
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	21
Safety of androgen therapy in men with prostate cancer	21
History of androgens and androgen action	20
Hyponatraemic encephalopathy	20
Localization in primary hyperparathyroidism	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	19
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	19
Editorial Board	19
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	19
Editorial Board	18
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Editorial Board	16
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	16
Diagnostic algorithm of hyponatremia	15
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	14
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	14
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	14
Chemokines in thyroid autoimmunity	14
Genotype-phenotype correlations in Graves’ disease	14
Mortality in craniopharyngiomas: Data from the last two decades	14
Care quality improvement in differences of sex development	14
Diagnosis and treatment of hypernatremia	14
Preface	14
Anaplastic thyroid cancer: An update	14
Hormone replacement in disorders of sex development, and long-term effects	14
COVID-induced thyroid autoimmunity	13
Preface	13
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	13
Addressing the social determinants of adverse outcomes in pregestational diabetes	13
Ectopic craniopharyngiomas	12
The epidemiology of disorders of sex development	12
Genetic endocrine tumours focusing on pituitary tumours	12
Strategies for improving the knowledge of patients and carers	12
Paraneoplastic autoimmune hypophysitis: An emerging concept	12

Editorial Board	12
Outcomes of pregnancies complicated by type 2 diabetes	12
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	11
Surgical treatment of thyroid cancer: Established and novel approaches	11
Quality of life in thyroid cancer	11
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	11
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
SARS-CoV-2 infection and its effects on the endocrine system	11
Covid-19 and endocrinology	11
Editorial Board	11
Editorial Board	11
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	10
New potential treatment options for syndrome of inappropriate antidiuresis	10
How best to monitor the specific side effects of medical treatments of Cushing’s disease	10
Endocrine abnormality in paraneoplastic syndrome	10
Hypopituitarism in patients with prolactinomas: a narrative review	10
Androgen-based therapies in women	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
Treatment of chronic hyponatremia and controversy about osmotic demyelination syndrome	9
Adolescent primary hyperparathyroidism	9
Burosumab: Current status and future prospects	8
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Editorial Board	8
Long-term thionamide antithyroid treatment of Graves' disease	8
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	8
COVID-19 vaccination and thyroiditis	8
Real-world value of cabergoline in the treatment of acromegaly	8
Management of patients with statin intolerance	8
Androgens part 2: Emerging areas	8
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	8
Preface	8
Current medical treatment and perspective in gonadotroph tumors	8
Hyponatraemia and cancer	7
Novel androgen therapies including selective androgen receptor modulators	7
Fertility and pregnancy in patients with prolactinoma	7
Pituitary and SARS CoV-2: An unremitting conundrum	7
Inherited fibroblast growth factor 23 excess	7
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	7
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	6
Tumor-induced osteomalacia: An overview	6
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	6
Resistant prolactinomas	6
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Vitamin D deficiency or resistance and hypophosphatemia	6
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Morbidity and mortality in men: Role of androgens	6
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	6
Traumatic brain injury and hypopituitarism	6
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
Innovative therapeutics in acromegaly	6
Hypothalamus-sparing surgery in craniopharyngiomas: Oncological and hypothalamic long-term outcomes	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Pituitary dysfunction due to sports injuries	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Diagnosis of gestational diabetes: Evidence and pitfalls	5
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	5
Broader impact and outcome of human NR5A1/SF1 variants	5
New advances in menopause symptom management	5
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	5
Impact of long-acting growth hormone replacement therapy in adult growth hormone deficiency: Comparison between adolescent, adult, and elderly patients	4
Androgens, sports, and detection strategies for anabolic drug use	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
The pathophysiology of hypophosphatemia	4
Pathophysiology and aetiologies of hypernatremia	4
Editorial Board	4
Growth hormone replacement therapy in childhood-onset craniopharyngioma	4
Editorial Board	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Congenital primary hyperparathyroidism	4
Editorial Board	4
Current views on the role of HIF-2α in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma	4
Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients	4
Premature ovarian insufficiency, early menopause, and induced menopause	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas	4
Primary hyperparathyroidism	4
Best practice and research, clinical endocrinology and metabolism preface to the special issue: Diagnosis and treatment of acromegaly acromegaly, a paradigmatic disease second part: Treatment	4